

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Qyuns Therapeutics Co., Ltd.
江蘇荃信生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2509)

INSIDE INFORMATION

COMPLETION OF THE H SHARE FULL CIRCULATION

This announcement is made by Qyuns Therapeutics Co., Ltd. (the “**Company**”) pursuant to Rule 13.09(2) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to (i) the announcement of the Company dated October 28, 2024 in relation to the acceptance by the China Securities Regulatory Commission (the “**CSRC**”) of the Company’s application to the CSRC for the proposed implementation of H share full circulation on behalf of certain shareholders of the Company (the “**Application**”); (ii) the announcement of the Company dated January 21, 2025 in relation to the issuance of filing notice by the CSRC for the Application; and (iii) the announcement of the Company dated March 13, 2025 in relation to the listing approval granted by the Stock Exchange regarding the listing of and permission to deal in 17,322,400 H shares (“**Converted H Shares**”) (together the “**Announcements**”). Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Announcements.

The Company is pleased to announce that the conversion of the 17,322,400 Unlisted Shares into H shares of the Company was completed on March 27, 2025, and the listing of the Converted H Shares on the Stock Exchange will commence at 9:00 a.m. on March 28, 2025 (the “**Conversion and Listing**”). The Participating Shareholders may conduct trading of the Converted H Shares subject to the completion of the applicable onshore arrangement procedures.

SHAREHOLDING STRUCTURE

The share capital structure of the Company immediately before and upon the completion of the Conversion and Listing is as follows:

Class of shares	Immediately prior to the completion of the Conversion and Listing of the Unlisted Shares		Upon completion of the Conversion and Listing of the Unlisted Shares	
	<i>Numbers of Shares</i>	<i>Percentage (approximately)</i>	<i>Numbers of Shares</i>	<i>Percentage (approximately)</i>
Unlisted Shares	17,322,400	7.80%	0	0%
H shares	204,749,200	92.20%	222,071,600	100%
Total number of issued shares	222,071,600	100%	222,071,600	100%

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Qyuns Therapeutics Co., Ltd.
Mr. Qiu Jiwan

Chairman of the Board and Executive Director

Hong Kong, March 27, 2025

As at the date of this announcement, the board of directors of the Company comprises Mr. Qiu Jiwan as chairman and executive director, Mr. Wu Yiliang and Mr. Lin Weidong as executive directors, Mr. Yu Xi and Mr. Wu Zhiqiang as non-executive directors, and Dr. Zou Zhongmei, Dr. Ling Jianqun and Mr. Fung Che Wai, Anthony as independent non-executive directors.